Introduction
Candida bloodstream infections are among the most common nosocomial infections and result in extremely high rates of mortality [1] . Knowledge of the rank order of occurrence and resistance profi les of various Candida species involved in bloodstream infections is important in order to establish empiric treatment protocols and to evaluate the potential impact of newer antifungal agents [2] . Several surveillance programs have documented variations in the distribution and resistance of Candida species over time and geographic area [3] [4] [5] . To date, only one multi-institutional surveillance study of Candida bloodstream isolates has been conducted in South Korea. In this earlier study [6] , the in vitro antifungal susceptibility isolates from eight hospitals to azole antifungal drugs (fl uconazole, itraconazole, and voriconazole) was determined and resistance to fl uconazole was found in only 2% of the Candida isolates.
In recent years, treatment of Candida bloodstream infections has been revolutionized with the introduction of newer antifungal agents, including the triazoles, fl uconazole, and voriconazole, and echinocandin antifungals [7] . In a new Infectious Diseases Society of America (IDSA) guideline, most changes in the management of Candida bloodstream infections relate to the appropriate use of echinocandins and the expanded action spectra of azoles [7] . However, multicenter data on in vitro antifungal activity of echinocandin antifungal agents against Candida bloodstream isolates is still lacking in South Korea. Furthermore, because antifungal susceptibility testing is not routinely performed in most South Korean hospitals, studies of trends in resistance to commonly used and newly introduced antifungal agents is not available. Therefore, we performed a multicenter surveillance study of bloodstream isolates of Candida species recovered from 20 tertiary hospitals in South Korea to investigate the current species distribution and in vitro susceptibility to fi ve antifungal agents (caspofungin, micafungin, amphotericin-B, fl uconazole, and voriconazole).
Material and methods

Candida isolates
All Candida bloodstream isolates were prospectively collected at the 20 tertiary hospitals in South Korea between September 2006 and August 2007. A total of 639 nonduplicate isolates of Candida species were evaluated and included the following; 242 isolates of Candida albicans, 167 Candida parapsilosis, 127 Candida tropicalis, 72 Candida glabrata, seven Candida guilliermondii, fi ve Candida lusitaniae, three Candida krusei, three Candida lipolytica, three Candida famata, and 10 isolates of other Candida species. All isolates were recovered from blood samples of patients admitted to all wards across all hospitals by the routine methods in use at each participating hospital. The BacT/Alert system (bioMérieux, Durham, NC) and the Bactec system (BD Microbiology, Sparks, MD) were used in 12 and eight hospitals, respectively. Duplicate isolates of the same Candida species from the same patient were excluded. Both the species identifi cation and the antifungal susceptibility were performed at the Chonnam National University Hospital. Species identifi cation was based on colony morphology using CHROMagar Candida, and the use of a commercial yeast identifi cation system (API 20C, bioMérieux, Marcy L'Étoile, France or the Vitek 2 system, Vitek 2 YST, bioMérieux).
Antifungal susceptibility testing
In vitro antifungal susceptibility testing to caspofungin, micafungin, amphotericin B, fl uconazole, and voriconazole was performed by a broth microdilution assay according to the methods of the Clinical and Laboratory Standards Institute (CLSI) M27-A3 [8] . The minimal inhibitory concentration (MIC) endpoints were read after 24 h of incubation in air at 35°C for caspofungin and micafungin, and after 48 h of incubation for all the other drugs. The MIC of amphotericin B was defi ned as complete inhibition of growth, while the MICs of fl uconazole, voriconazole, caspofungin, and micafungin were defi ned as the lowest concentrations that produced a prominent decrease in turbidity (approximately 50%) relative to a drug-free control. Two reference strains, C. parapsilosis ATCC 22019 and C. krusei ATCC 6258, were included as quality control isolates in each test. Interpretative criteria for susceptibility of caspofungin, micafungin, fl uconazole, and voriconazole were those indicated in the CLSI document M27-A3 [8] .
Results and discussion
In a 1-year surveillance program, 639 Candida species bloodstream isolates were collected from 20 tertiary hospitals (Table 1) . To date, no surveillance study of this magnitude has been conducted in South Korea to examine the distribution of Candida species recovered from blood samples or their antifungal drug susceptibility. This study not only expands the number of participating hospitals from 8 to 20, but examines antifungal drug susceptibilities of isolates to echinocandins, as well as to the azoles.
The number of bloodstream isolates from each hospital varied considerably, ranging from four to 125. Generally, higher isolation (≥19 isolates) was noted in the hospitals with >800 beds (hospitals 1-7, 9-12) than in the other nine hospitals, which each have 300-800 beds. The Candida species recovered most frequently from the blood samples were as follows; C. albicans (38%), C. parapsilosis (26%), C. tropicalis (20%), and C. glabrata (11%). C. parapsilosis was the most common non-C. albicans Candida species in South Korea [6] , as has been reported in Japan [5] and Latin America [9] . Overall, 62% of the bloodstream isolates were non-C. albicans Candida species, which was an increase in frequency of non-C. albicans Candida in comparison to the results noted in our previous study (51%) [6] . Of ten hospitals reporting the higher recovery of Candida isolates (≥19 isolates), hospital 8, which had a higher population of immunocompromised patients (mainly hematological malignancies), showed the highest proportion of non-C. albicans Candida species (77.2%).
Although C. glabrata was the most common species after C. albicans isolated in both North America and Europe [9], C. glabrata was the 4th most common Candida species recovered from the blood in this study, which is consistent with our previous report [6] . In addition, it appears that substantial differences exist in the species distribution between different hospitals. Although C. albicans remained the dominant species causing bloodstream infections in most hospitals, C. parapsilosis was the most common cause of such infections in three of 20 hospitals. Whereas C. glabrata was the second most common Candida species isolated in two hospitals (hospital 1, and equal to C. parapsilosis in hospital 5), no C. glabrata isolates were recovered from 6 of 20 hospitals.
The in vitro antifungal susceptibility of the 639 isolates to 5 antifungal agents is shown in Table 2 . When read at 24 h of incubation using the prominent reduction endpoint criterion [8] , C. albicans, C. tropicalis, and C. glabrata showed high susceptibility to caspofungin (MIC 90 , 0.06-0.125 μg/ml) and micafungin (MIC 90 , 0.03 μg/ml), whereas C. parapsilosis and other miscel laneous Candida species were less susceptible to cas pofungin (MIC 90 , 1 μg/ml) and micafungin (MIC 90 , 0.125-0.25 μg/ml).
These data refl ect the reduced susceptibilities of species, such as C. parapsilosis and the less common Candida species relative to those of C. albicans, C. glabrata, and C. tropicalis, as noted previously [9] . Although miscellaneous Candida species accounted for only 5% of all Candida bloodstream infections in South Korea, they included C. guilliermondii, C. lipolytica, and C. famata, which have been reported to be less susceptible to both caspofungin and micafungin than other species [9] . The current data indicate that no global shift in caspofungin and micafungin MICs distribution of Candida species isolates was observed over time, with 99.9% to 100% of isolates inhibited by Յ 2 μg/ml [10] . However, echinocandin-resistant Candida isolates have recently emerged following treatment with this class of antifungal agents [10] . In the present report, 100% of the isolates were classifi ed as susceptible to both echinocandins tested based a R and SDD, resistant-and susceptible-dose dependent, by using the interpretive breakpoint criteria of the CLSI M27-A3 [8] .
b All three C. krusei isolates are considered as resistant to fl uconazole, irrespective of the MIC. c Includes C. guilliermondii (7 isolates), C. lusitaniae (5 isolates), C. krusei (3 isolates), C. lipolytica (3 isolates), C. famata (3 isolates), C. utilis (2 isolates), C. pelliculosa (1 isolate), C. kefyr (1 isolate), C. pseudohaemulonii (1 isolate), C. catenulata (1 isolate), C. rugosa (1 isolate), C. intermedia (1 isolate) and 2 unidentifi ed Candida isolates.
on the Յ 2 μg/ml CLSI breakpoint [8] , which may refl ect the limited use of echinocandin drugs in South Korean hospitals [11] . The amphotericin B MICs were Յ 1 μg/ml for nearly all isolates (99.7%). The amphotericin B MICs for two Candida isolates (C. parapsilosis and C. pseudohaemulonii) were 2 μg/ml by the CLSI method, but the MICs were 2 and 32 μg/ml by the Etest, respectively. Recently, we have described seven cases of C. pseudohaemulonii fungemia identifi ed at two hospitals in South Korea [12] . All of these isolates were susceptible to fl uconazole, voriconazole, micafungin, and caspofungin, but isolates from fi ve patients showed high-level amphotericin B resistance (MIC, 32 μg/ml) by the Etest [12] . During the present study period (September 2006 to August 2007 , only one isolate of C. pseudohaemulonii (which was susceptible to azole and echinocandin antifungal agents and resistant to amphotericin B) was recovered.
According to the ARTEMIS DISK Global Antifungal Surveillance Study [4] , the percentages of isolates resistant to fl uconazole and voriconazole have been reported to be 6.2% and 3.1%, respectively. Another multicenter study of antifungal drug susceptibility, as determined by the CLSI broth microdilution method, showed that 3% and 6% of Candida species isolates were fl uconazole-resistant and susceptible, dose-dependent (SDD), respectively [13] . In the present study, resistance to fl uconazole existed in only 0.8% (5/639) of the Candida isolates (two C. glabrata isolates and three C. krusei), and SDD existed in 2.8% (18/639) of the isolates (one C. albicans isolate and 17 C. glabrata). Furthermore, resistance to fl uconazole among isolates of C. glabrata (2.8%) is still less than those of other geographic regions (13.5-20.5%) [4] . Therefore, the relatively lower percentages of resistance to fl uconazole among Candida species isolates in South Korea may be explained by not only the lower proportion of C. glabrata isolates found among all Candida bloodstream isolates, but the lower percentage of fl uconazole-resistant C. glabrata isolates recovered.
The resistance rate to voriconazole was 0.3% and was found in only two Candida isolates (one C. glabrata isolate and one C. krusei isolate). The number of resistant isolates to fl uconazole or voriconazole was low (0-3) in all of the hospitals, and no signifi cant differences were detected in antifungal susceptibility patterns among hospitals. Overall, our data show that the rate of resistance to azole antifungals is still low among isolates recovered from bloodstream samples in South Korea. This suggests the sustained usefulness of fl uconazole for the treatment of Candida bloodstream infections in this country. However, this data which documents the antifungal susceptibilities of Candida bloodstream isolates collected from 2006-2007 might not represent its current (2008) (2009) and future status. Therefore, continuous surveillance of Candida species distribution and antifungal susceptibility trends is needed.
In conclusion, we have shown for the fi rst time that all of Candida species recovered from bloodstream samples at 20 South Korean hospitals were classifi ed as susceptible to both caspofungin and micafungin based on the CLSI breakpoint. However, C. parapsilosis and miscellaneous Candida species isolates were relatively less susceptible to both echinocandins. Among the bloodstream isolates, the non-C. albicans Candida species have increased to over 60% of all Candida species recovered. C. parapsilosis is the second leading cause of candidemia in South Korea. The rates of resistance to amphotericin B, fl uconazole, and voriconazole are still low among bloodstream isolates in South Korea. This report serves to make available information for the selection of empirical antifungals for candidemic patients in South Korea and emphasizes the importance of multicenter surveillance for Candida bloodstream infections.
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